CSTL Castle Biosciences

Castle Biosciences to Present at the 19th Annual Needham Virtual Healthcare Conference

FRIENDSWOOD, Texas--(BUSINESS WIRE)--

Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that Derek Maetzold, president and chief executive officer, is scheduled to present a company overview at the 19th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2020, at 3:30 p.m. Eastern time.

A live audio webcast of the company’s presentation will be available by visiting Castle Biosciences’ website at . A replay of the webcast will be available for two weeks following the conclusion of the live broadcast.

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a commercial-stage dermatologic cancer company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company currently offers tests for patients with cutaneous melanoma (DecisionDx®-Melanoma, DecisionDx®-CMSeq; ) and uveal melanoma (DecisionDx®-UM, DecisionDx®-PRAME and DecisionDx®-UMSeq; ), with products in development for other underserved cancers, the two most advanced of which are focused on patients with cutaneous squamous cell carcinoma, and patients who have a difficult-to-diagnose pigmented lesion. Castle Biosciences is based in Friendswood, Texas (Houston), and has laboratory operations in Phoenix, Arizona. For more information, visit .

DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.

EN
06/04/2020

Underlying

CSTLCastle Biosciences

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Castle Biosciences

 PRESS RELEASE
Free
CSTL Castle Bioscien...

Castle Biosciences Honored with a Greater Pittsburgh Top Workplaces 20...

Castle Biosciences Honored with a Greater Pittsburgh Top Workplaces 2025 Award FRIENDSWOOD, Texas, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been recognized as a Greater Pittsburgh Top Workplace by The Pittsburgh Post-Gazette. The designation is based exclusively on anonymous employee feedback gathered through a third-party survey. The confidential survey measures several aspects of workplace culture designed to be indicative of employee satisfaction a...

September 23, 2025 1 EN
 PRESS RELEASE
Free
CSTL Castle Bioscien...

Castle Biosciences Named One of Newsweek’s America’s Greatest Companie...

Castle Biosciences Named One of Newsweek’s America’s Greatest Companies 2025 FRIENDSWOOD, Texas, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, has been included in the inaugural list, published by Newsweek. The ranking honors 650 U.S. companies demonstrating strong performance across four key pillars: financial strength, workforce dedication, innovation, and commitment to environmental sustainability and corporate ethics. “This recognition from Newsweek underscores the power of our...

September 17, 2025 1 EN
 PRESS RELEASE
Free
CSTL Castle Bioscien...

New Data at American Foregut Society's 2025 Annual Meeting Demonstrate...

New Data at American Foregut Society's 2025 Annual Meeting Demonstrates TissueCypher® Can Detect High-Risk Barrett’s Esophagus Patients Not Identified by Pathology to Support Improved Care Decisions In the study, TissueCypher identified that 15% of patients with non-dysplastic Barrett's esophagus (NDBE) had a probability of progression that was similar to, or exceeded, progression rates associated with low-grade dysplasia (LGD); current guidelines recommend prompt intervention for LGD to prevent disease progression FRIENDSWOOD, Texas, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Castle Bioscience...

September 9, 2025 1 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 42.57
FICO FAIR ISAAC CORP...
PSTG Pure Storage I... ... (+25)

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

FICO FAIR ISAAC CORPORATION
PSTG PURE STORAGE INC. CLASS A
PAHC PHIBRO ANIMAL HEALTH CORPORATION CLASS A
NTAP NETAPP INC.
LPTH LIGHTPATH TECHNOLOGIES INC. CL A
A AGILENT TECHNOLOGIES INC.
AGX ARGAN INC.
ELF E.L.F. BEAUTY INC.
CHCI COMSTOCK HOLDING COMPANIES
RCMT RCM TECHNOLOGIES
STNE STONECO
CSTL CASTLE BIOSCIENCES
SOFI SOFI TECHNOLOGIES INC
IMRX IMMUNEERING CORP
DSGN DESIGN THERAPEUTICS INC
FTAI FORTRESS TRANSN & INFRAS INVS LLC
ASPI ASP ISOTOPES INC
FTREV FORTREA HOLDINGS INC.
KRRO KORRO BIO INC
RAPP RAPPORT THERAPEUTICS INC
ALMU AELUMA INC
RHLD RESOLUTE HOLDINGS MANAGEMENT INC
ASST ASSET ENTITIES INC
SNDK SANDISK CORP
INFU MULTI UNITS LU - AMUNDI US INFLATION EXPECTATIONS 10Y
08/29/25 August 29, 2025 1 EN
 PRESS RELEASE
Free
CSTL Castle Bioscien...

New Evidence Published Supporting Use of DecisionDx®-SCC Test in Guidi...

New Evidence Published Supporting Use of DecisionDx®-SCC Test in Guiding and Improving Treatment Pathway Decisions in NCCN High-Risk Cutaneous Squamous Cell Carcinoma New validation study shows DecisionDx-SCC significantly outperforms current staging systems in predicting risk of local recurrence and metastasis for NCCN high-risk patients Clinician survey confirms test results align with treatment decision-making thresholds for adjuvant radiation therapy and surveillance imaging FRIENDSWOOD, Texas, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company impr...

August 25, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch